

(19)  Canadian
Intellectual Property
Office

An Agency of
Industry Canada

Office de la Propriété,
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

(11) **CA 2 078 666**

(13) **C**

(40) 02.10.2001

(43) 03.10.1991

(45) 02.10.2001

(12)

(21) **2 078 666**

(22) **20.03.1991**

(51) Int. Cl. 5: **A61K 9/127**

(85) **18.09.1992**

(86) **PCT/US91/01849**

(87) **WO91/14445**

(30) **496,846 US 21.03.1990**

(73)

SKYEPHARMA INC.
10450 Science Center Drive SAN DIEGO XX (US).

(72)

Kim, Sinil (US).

(74)


BORDEN LADNER GERVAIS LLP

(54) **LIPOSOMES HETEROVESICULAIRES**

(54) **HETEROVESICULAR LIPOSOMES**

(57)

²²²²Disclosed are heterovesicular liposomes containing different biological ²compositions (14, 14a) each encapsulated in separate chambers of the liposomes, having defined size distribution, adjustable ²internal chamber size and number, methods of making them and treatment of patients with them. The preparation process includes ²the addition of composition to first lipid component in the vial to obtain an emulsion, the addition of composition to second ²lipid component in the vial to obtain a second emulsion and mixing these emulsions to form a chimeric emulsion.²





Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2078666 C 2001/10/02

(11)(21) **2 078 666**


(12) **BREVET CANADIEN
CANADIAN PATENT**

(13) **C**

(86) Date de dépôt PCT/PCT Filing Date: 1991/03/20
(87) Date publication PCT/PCT Publication Date: 1991/10/03
(45) Date de délivrance/Issue Date: 2001/10/02
(85) Entrée phase nationale/National Entry: 1992/09/18
(86) N° demande PCT/PCT Application No.: US 91/01849
(87) N° publication PCT/PCT Publication No.: WO 91/14445
(30) Priorité/Priority: 1990/03/21 (496,846) US

(51) Cl.Int.⁵/Int.Cl.⁵ A61K 9/127
(72) Inventeur/Inventor:
Kim, Sinil, US
(73) Propriétaire/Owner:
SKYEPHARMA INC., US
(74) Agent: BORDEN LADNER GERVAIS LLP

(54) Titre : LIPOSOMES HETEROVESICULAIRES
(54) Title: HETEROVESICULAR LIPOSOMES



(57) Abrégé/Abstract:

Disclosed are heterovesicular liposomes containing different biological compositions (14, 14a) each encapsulated in separate chambers of the liposomes, having defined size distribution, adjustable internal chamber size and number, methods of making them and treatment of patients with them. The preparation process includes the addition of composition to first lipid component in the vial to obtain an emulsion, the addition of composition to second lipid component in the vial to obtain a second emulsion and mixing these emulsions to form a chimeric emulsion.

Canada

<http://opic.gc.ca> • Ottawa-Hull K1A 0C9 • <http://cipo.gc.ca>

OPIC • CIPQ 191

OPIC



CIPO



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61K 37/22, B01J 13/02	A1	(11) International Publication Number: WO 91/14445 (43) International Publication Date: 3 October 1991 (03.10.91)
--	----	--

(21) International Application Number 2078666 PCT/US91/01849

(22) International Filing Date: 20 March 1991 (20.03.91)

(30) Priority data:
496,846 21 March 1990 (21.03.90) US

(71) Applicant: RESEARCH DEVELOPMENT FOUNDATION [US/US]; 402 North Division Street, Carson City, NV 89703 (US).


(72) Inventor: KIM, Sinil ; 548 Ford Avenue, Solana Beach, CA 92705 (US).

(74) Agent: WEILER, James, F.; One Riverway, Suite 1560, Houston, TX 77056 (US).

(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), NO, SE (European patent), SU.

Published
With international search report.

(54) Title: HETEROVESICULAR LIPOSOMES



(57) Abstract

Disclosed are heterovesicular liposomes containing different biological compositions (14, 14a) each encapsulated in separate chambers of the liposomes, having defined size distribution, adjustable internal chamber size and number, methods of making them and treatment of patients with them. The preparation process includes the addition of composition to first lipid component in the vial to obtain an emulsion, the addition of composition to second lipid component in the vial to obtain a second emulsion and mixing these emulsions to form a chimeric emulsion.

2078666

-1-

HETEROVESICULAR LIPOSOMESField of the Invention

The invention relates to the synthetic
5 heterovesicular lipid vesicles or liposomes, processes for
their manufacture and encapsulation of various materials
therein, and treatment of patients with them.

Background Art

Multivesicular liposomes are one of the three main
10 types of liposomes, first made by Kim, et al. (1983,
Biochim. Biophys. Acta 782, 339-348), and are uniquely
different from the unilamellar (Huang, 1969, Biochemistry
8,344-352; Kim, et al. 1981, Biochim. Biophys. Acta 646,
1-10) and multilamellar (Bangham, et al. 1965, J. Mol. Bio.
15 13,238-252) liposomes in that there are multiple non-
concentric aqueous chambers within. Previously described
techniques for producing liposomes relate to the production
of non-multivesicular liposomes; for example, U.S. Patent
Nos. 4,522,803 - Lenk, 4,310,506 - Baldeschwieler,
20 4,235,871 - Papahadjopoulos, 4,224,179 - 4,078,052 -
Papahadjopoulos, 4,394,372 - Taylor, 4,308,166 - Marchetti,
4,485,054 - Mezei, and 4,508,703 - Redziniak. For a
comprehensive review of various methods of liposome
preparation, refer to Szoka, et al. 1980, Ann. Rev. Biophys.
25 Bioeng. 9:467-508.

Heterovesicular liposomes are lipid vesicles or
liposomes with multiple internal aqueous chambers where at
least two substances of different compositions are each
encapsulated in separate chambers within one liposomes. The
30 lipid vesicles or liposomes with multiple internal aqueous

2078666

-2-

chambers include, but are not limited to, multilamellar liposomes, stable paucilamellar liposomes, and multivesicular liposomes. It is highly advantageous to provide a liposome delivery system in which two or more
5 different substances are each encapsulated in separate compartments of a single liposome rather than encapsulated together in each compartment of the liposome.

Summary of the Invention

The composition of the present invention comprises
10 heterovesicular liposomes, i.e. lipid vesicles or liposomes with multiple internal aqueous chambers where two or more substances of different compositions are each encapsulated separately in different chambers within one liposome.

Briefly, the method of the invention comprises
15 making a "water-in-lipid" emulsion by dissolving amphipathic lipids in one or more organic solvents for the first lipid component, adding an immiscible first aqueous component including a substance to be encapsulated, preferably in the presence of hydrochloric acid, and then emulsifying the
20 mixture mechanically. In the emulsion, the water droplets suspended in the organic solvent will form the internal aqueous chambers, and the monolayer of amphipathic lipids lining the aqueous chambers will become one leaflet of the bilayer membrane in the final product. A second lipid
25 component is then formed by dissolving amphipathic lipids in a volatile organic solvent and adding an immiscible second aqueous component including a second substance to be encapsulated, preferably in the presence of hydrochloric acid. A second emulsion is then created. A chimeric
30 emulsion is then formed by combining the first and second emulsions. The chimeric emulsion consists of multiple water droplets suspended in organic solvent where the substances of two different compositions are each dissolved separately in different aqueous droplets. The chimeric emulsion is
35 then immersed in a third aqueous immiscible component preferably containing one or more nonionic osmotic agents

2078666

-3-

and acid-neutralizing agent of low ionic strength and then mechanically dividing it to form solvent spherules suspended in the third aqueous component. The solvent spherules contain multiple aqueous droplets where the substances of two different compositions are each dissolved separately in different aqueous droplets within a single solvent spherule. The volatile organic solvent is evaporated from the spherules preferably by passing a stream of gas over the suspension. When the solvent is completely evaporated, the spherules convert into heterovesicular liposomes with multiple internal aqueous chambers where two substances of different compositions are encapsulated separately in different chambers within one liposome.

The use of hydrochloric acid with a neutralizing agent, or other hydrochlorides which slow leakage rates is preferably for high encapsulation efficiency and for a slow leakage rate of encapsulated molecules in biological fluids and in vivo. It is also preferable to use neutralizing agent of low ionic strength to prevent solvent spherules from sticking to each other.

Accordingly, it is an object of the present invention to provide a heterovesicular lipid vesicle or liposome having at least two substances of different compositions each encapsulated separately in different chambers of the vesicle or liposome.

A further object of the present invention is the provision of a heterovesicular liposome containing at least two biologically active substances of different compositions each encapsulated separately in chambers of the liposome in the presence of hydrochloric acid or other hydrochlorides which slow the leakage of them.

It is a further object of the present invention to provide a heterovesicular liposome containing at least two biologically active substances of different compositions each encapsulated separately in chambers of the liposome in

2073666

-4-

the presence of hydrochloric acid or other hydrochlorides and a neutralizing agent.

It is a further object of the present invention to provide methods of producing such heterovesicular lipid vesicles or liposomes.

It is a further object of the present invention to provide processes for producing such heterovesicular lipid vesicles or liposomes by providing a first lipid component dissolved in one or more organic solvents and adding to the lipid component an immiscible first aqueous component containing a first substance to be encapsulated, forming a first water in oil emulsion from the first two immiscible components, providing a second lipid component dissolved in one or more organic solvents and adding into the lipid component an immiscible second aqueous component containing a second substance to be encapsulated, forming a second water in oil emulsion from the second two immiscible components, forming a chimeric emulsion by combining the first water in oil emulsion and second water in oil emulsion, transferring and immersing the chimeric emulsion into a third immiscible aqueous component, dispersing the chimeric emulsion to form solvent spherules containing multiple droplets of the first aqueous component containing the first substance and the second aqueous component containing the second substance, and evaporating the organic solvent from the solvent spherules to form the heterovesicular lipid vesicles or liposomes.

It is a further object to provide such a process in which a variety of hydrophilic biologically active materials and can be encapsulated separately in chambers of the heterovesicular lipid vesicles or liposomes.

It is a further object of the present invention to provide a method for the treatment of a patient with at least two separate biologically active substances of different compositions by administering them to the patient

2078666

-5-

encapsulated separately in chambers of a heterovesicular vesicle or liposome.

Other and further objects, features and advantages of the invention appear throughout the specification and claims.

Brief Description of the Drawings

Figures 1-8 are schematic diagrams illustrating preparation of a heterovesicular vesicle or liposome.

Description of Preferred Embodiments

10 The term "multivesicular liposomes" as used throughout the specification and claims means man-made, microscopic lipid-vesicles consisting of lipid bilayer membranes, enclosing multiple non-concentric aqueous chambers which all contain the same component. In contrast,
15 the term "heterovesicular liposomes as used throughout the specification and claims means man-made, microscopic liquid vesicles consisting of lipid bilayer membranes enclosing multiple, aqueous chamber wherein at least two of the chambers separately contain substances of different
20 compositions. The microscopic lipid vesicles include but are not limited to multilamellar liposomes, stable paucilamellar liposomes, and multivesicular liposomes.

 The term "chimeric emulsion" as used throughout the specification and claims means an emulsion that consists
25 of multiple water droplets suspended in organic solvent where the substances of two different compositions are each dissolved separately in different aqueous droplets.

 The term "solvent spherule" as used throughout the specification and claims means a microscopic spheroid
30 droplet of organic solvent, within which is multiple smaller droplets of aqueous solution. The solvent spherules are suspended and totally immersed in a second aqueous solution.

 The term "neutral lipid" means oil or fats that have no membrane-forming capability by themselves and lack a
35 hydrophilic "head" group.

2078666

-6-

The term amphipathic lipids means those molecules that have a hydrophilic "head" group and hydrophobic "tail" group and have membrane-forming capability.

The composition of the present invention is a
 5 heterovesicular lipid vesicle or liposome having at least two substances of different compositions each encapsulated separately in different chambers of the vesicle or liposome.

Many and varied biological substances can be incorporated by encapsulation within the multivesicular
 10 liposomes. These include drugs, and other kinds of materials, such as DNA, RNA, proteins of various types, protein hormones produced by recombinant DNA technology effective in humans, hematopoietic growth factors, monokines, lymphokines, tumor necrosis factor, inhibin,
 15 tumor growth factor alpha and beta, mullerian inhibitory substance, nerve growth factor, fibroblast growth factor, platelet-derived growth factor, pituitary and hypophyseal hormones including LH and other releasing hormones, calcitonin, proteins that serve as immunogens for
 20 vaccination, and DNA and RNA sequences.

The following Table 1 includes a list of representative biologically active substances which can be encapsulated in heterovesicular liposomes in the presence of a hydrochloride and which are effective in humans.

25

TABLE 1

<u>Antiasthma</u>	<u>Antiarrhythmic</u>	<u>Tranquillizers</u>
metaproterenol	propanolol	chlorpromazine
aminophylline	atenolol	benzodiazepine
theophylline	verapamil	butyrophenones
30 terbutaline	captopril	hydroxyzines
Tegretol	isosorbide	meprobamate
ephedrine		phenothiazines
isoproterenol		reserpine
adrenalin		thioxanthines
35 norepinephrine		

2078666

-7-

	<u>Cardiac glycosides</u>	<u>Hormones</u>	<u>Steroids</u>
	digitalis	antidiuretic	prednisone
	digitoxin	corticosteroids	triamcinolone
	lanatoside C	testosterone	hydrocortisone
5	digoxin	estrogen	dexamethasone
		thyroid	betamethasone
		growth	prednisolone
		ACTH	
		progesterone	
10		gonadotropin	
		mineralocorticoid	
		LH	
		LHRH	
		FSH	
15		calcitonin	
	<u>Antihypertensives</u>	<u>Antidiabetic</u>	<u>Antihistamines</u>
	apresoline	Diabenese	pyribenzamine
	atenolol	insulin	chlorpheniramine
			diphenhydramine
20	<u>Antiparasitic</u>	<u>Anticancer</u>	<u>Sedatives & Analgesic</u>
	praziquantel	azathloprine	morphine
	metronidazole	bleomycin	dilaudid
	pentamidine	cyclophosphamide	codeine
		adriamycin	codeine-like synthetics
25		daunorubicin	demerol
		vincristine	oxymorphone
		methotrexate	phenobarbital
		6-TG	barbiturates
		6-MP	
30		vinblastine	
		VP-16	
		VM-26	
		cisplatin	
		FU	
35	<u>Antibiotic</u>	<u>Immunotherapies</u>	<u>Vaccines</u>
	penicillin	interferon	influenza
	tetracycline	interleukin-2	respiratory syncytial
	erythromycin	monoclonal antibodies	virus
	cephalothin	gamma globulin	Hemophilus influenza
40	imipenem		vaccine
	cefotaxime		
	carbenicillin		

2078666

-8-

	<u>Antibiotic (continued)</u>	<u>Antifungal</u>	<u>Antiviral</u>
	vancomycin	amphotericin B	acyclovir and deriva-
	gentamycin	myconazole	tives
	tobramycin	muramyl dipeptide	Winthrop-51711
5	piperacillin	clotrimazole	ribavirin
	moxalactam		rimantadine/amantadine
	amoxicillin		azidothymidine & deriva-
	ampicillin	<u>Antihypotension</u>	tives
	cefazolin	dopamine	adenine arabinoside
10	cefadroxil	dextroamphetamine	amidine-type protease
	cefoxitin		inhibitors
	other aminoglycosides		
	<u>Proteins and Glycoproteins</u>		<u>Other</u>
	lymphokines		cell surface receptor
15	interleukins - 1, 2, 3, 4, 5, and 6		blockers
	cytokines		
	GM-CSF		<u>Nucleic Acids & Analogs</u>
	M-CSF		DNA
	G-CSF		RNA
20	tumor necrosis factor		methylphosphonates
	inhibin		and analogs
	tumor growth factor		
	Mullerian inhibitors substance		
	nerve growth factor		
25	fibroblast growth factor		
	platelet derived growth factor		
	coagulation factors (e.g. VIII, IX, VII)		
	insulin		
	tissue plasminogen activator		
30	histocompatibility antigen		
	oncogene products		
	myelin basic protein		
	collagen		
	fibronectin		
35	laminin		
	other proteins made by recombinant DNA		
	technology		

40 A preferred method of making the heterovesicular vesicle or liposome is illustrated in the drawing to which reference is now made. In step 1 (Figure 1) a first aqueous substance of composition 10 to be encapsulated is added to a

2078666

-9-

first lipid component 12 in the vial 14. The vial 14 is sealed and in step 2 (Figure 2) is mixed and shaken, such as being attached to the head of a vortex mixer to form the first water in oil emulsion 16 containing the first substance of composition 10 to be encapsulated. In step 3 (Figure 3), a second vial 14a, a second aqueous 10a to be encapsulated is added to a second lipid component 12a, and the vial 14a is sealed and in step 4 (Figure 4) is mixed, such as being attached to the head of a vortex mixer to form a second water-in-oil emulsion 16a containing the substance of composition 10a to be encapsulated.

In step 5 (Figure 5) the first 16 and second 16a water in oil emulsions are added together and mixed, such as by hand to make a "chimeric" emulsion.

In step 6 (Figure 6) a portion of the chimeric emulsion from step 5 is individually added to vials containing a third immiscible aqueous component 18a such as by squirting rapidly through a narrow tip pasteur pipette into two one-dram vials, here shown as one.

In step 7 (Figure 7) vials from step 6 are shaken, such as by a vortex mixer, and in step 8 (Figure 8) the chloroform spherule suspension in each vial is transferred from step 7 and the chloroform is evaporated, such as by a stream of nitrogen gas, thereby providing the heterovesicular liposome that contains a first substance in one or more internal aqueous chambers and a second substance in the remaining internal aqueous chambers within a single liposome.

Preferably, each of the substances to be encapsulated are encapsulated in the presence of a hydrochloride, such as hydrochloric acid, which slows their leakage rate from the liposome or vesicle.

As previously mentioned, any biologically active substance, such as illustrated in Table 1, can be encapsulated separately in chambers of the vesicle or liposome.

2078666

-10-

The following examples set forth presently preferred methods of encapsulating two substances of different compositions in separate chambers of a vesicle or liposome.

5

Example 1Preparation of Dideoxycytidine/GlucoseHeterovesicular Liposomes

10 Step 1: A first aqueous substance (one ml of 20 mg/ml dideoxycytidine solution in water with 0.1 N hydrochloric acid) was added into a one-dram vial containing the first lipid component (9.3 umoles of dioleoyl lecithin, 2.1 umoles of dipalmitoyl phosphatidylglycerol, 15 umoles of cholesterol, 1.8 umoles of triolein and one ml of chloroform).

15 Step 2: The first vial was sealed and attached to the head of a vortex mixer and shaken at maximum speed for 6 minutes to form the first water-in-oil emulsion.

20 Step 3: In second vial, the second aqueous substance (one ml of 30 mg/ml glucose solution in water with 0.1 N hydrochloric acid) was added into the second lipid component (which is identical to the first lipid component).

Step 4: The second vial was sealed and attached to the head of a vortex mixer and shaken at maximum speed for 6 minutes to form the second water-in-oil emulsion.

25 Step 5: 0.5 ml of the first emulsion was added to the second vial and mixed by hand to make a "chimeric" emulsion.

30 Step 6: Half of the "chimeric" emulsion was individually squirted rapidly through a narrow tip Pasteur pipette into one-dram vials, each containing a third immiscible aqueous component (2.5 ml water, 32 mg/ml glucose, 40 mM free-base lysine).

35 Step 7: The vials from step 6 were shaken on the vortex mixer for 3 seconds at "5" setting to form solvent spherules containing multiple droplets of the first and second aqueous substances within.

2078666

-11-

Step 8: The chloroform spherule suspensions in each vials were transferred into the bottom of a 2 L beaker containing 4.5 ml of water, 35 mg/ml glucose, and 22 mM free-base lysine. A stream of nitrogen gas at 7 L/min was
5 flushed through the beaker to evaporate chloroform over 5 minutes at 15 deg. C.

The above example describes a method of making heterovesicular liposomes which separately contain glucose in approximately 5/6 of the internal aqueous chambers and
10 separately contain dideoxycytidine in the remaining 1/6 of the internal aqueous chambers within a single liposome. Heterovesicular liposomes containing dideoxycytidine solution as one aqueous substance and glucose as the second aqueous substance were markedly more stable than non-
15 heterovesicular liposomes.

Example 2

This example is for the synthesis of heterovesicular liposomes containing IL-2 (interleukin-2) and lysine hydrochloride: For each batch of liposomes
20 prepared, one ml of water containing 10 mg/ml HSA (Human serum albumin), 1 ug of IL-2, 200 mM lysine HCl pH 7.13 was added into a one-dram vial containing 9.3 umoles of dioleoyl lecithin, 2.1 umoles of dipalmitoyl phosphatidylglycerol, 15 umoles of cholesterol, and 1.8 umoles of triolein and one ml
25 of chloroform (this is the first water-in-oil emulsion). For the second water-in-oil emulsion, 1 ml of lysine HCl (without IL-2) was added into one-dram vial containing 9.3 umoles of dioleoyl lecithin, 2.1 umoles of dipalmitoyl phosphatidylglycerol, 15 umoles of cholesterol, and 1.87
30 umoles of triolein and one ml of chloroform. Each of the two vials were individually attached to the head of a vortex mixer and shaken sequentially at the maximum speed for 6 minutes.

0.5 ml of the first water-in-oil emulsion was
35 added to the 2 ml of the second emulsion and mixed to make a "chimeric" water-in-oil emulsion. Half of the "chimeric"

2078666

-12-

emulsion was individually squirted rapidly through a narrow tip Pasteur pipette into one-dram vials, each containing 2.5 ml of 4% glucose in water and 0.1 ml of lysine free base, 200 mM, and shaken at maximum speed for 3 seconds to form chloroform spherules. The chloroform spherule suspensions were transferred into 250 ml Erlenmeyer flask containing 5 ml of 4% glucose in water and 0.2 ml of lysine free base, 200 mM. A stream of nitrogen gas at 7 L/min was flushed through the flask to evaporate chloroform over 5 minutes at 37 degrees C.

Example 3

This example is for the synthesis of heterovesicular liposomes containing ara-C solution as the first aqueous substance and distilled water as the second aqueous substance. For each batch of liposomes prepared, one ml of water containing 100 mg/ml ara-C, pH 1.1 was added into a one-dram vial containing 9.3 umoles of dioleoyl lecithin, 2.1 umoles of dipalmitoyl phosphatidylglycerol, 15 umoles of cholesterol, and 1.8 umoles of triolein and one ml of chloroform, attached to the head of the vortex mixer and shaken at maximum speed for 6 minutes (this is the first water-in-oil emulsion). For the in situ generation of the second water-in-oil emulsion, 1/2 of the content was removed from the first water-in-oil emulsion, and then 1 ml of distilled water was added into the remaining first water-in-oil emulsion and the one-dram vial was shaken for 10 seconds at maximum speed. This resulted in a "chimeric" water-in-oil emulsion. Half of the "chimeric" emulsion was individually squiired rapidly through a narrow tip Pasteur pipette into one-dram vials, each containing 2.0 ml of 4% glucose in water and 0.5 ml of lysine free base, 200 mM, and shaken at maximum speed for 3 seconds to form chloroform spherules. The chloroform spherule suspensions were transferred into 250 ml Erlenmeyer flask containing 4 ml. of 4% glucose in water and 0.5 ml of lysine free base, 200 mM. A stream of nitrogen gas at 7 L/min was flushed through the

-13- 2078666

flask to evaporate chloroform over 5 minutes at 37 degrees C.

Example 4

Synthesis of Heterovesicular Liposomes Containing Granulocyte-Macrophase Colony Stimulating Factor (GM-CSF)

5

Exactly the same procedure was used as in Example 2 except IL-2 was replaced with 1 ug of GM-CSF.

Example 5

10

Synthesis of Heterovesicular Liposomes of Various Lipid Composition, and Incorporation of Various Materials into Liposomes

In place of using dioleoyl lecithin, dipalmitoyl phosphatidylglycerol, cholesterol, and triolein (TO), and other amphipathic lipids such as phosphatidyl cholines (PC), cardiolipin (CL), dimyristoyl phosphatidylglycerol (DMPG), phosphatidyl ethanolamines (PE), phosphatidyl serines (PS), dimyristoyl phosphatidic acid (DMPA), and other neutral lipids such as tricaprylin (TC) in various combination can be used with similar results. For example, PC/C/CL/TO in 4.5/4.5/1/1 molar ration; DOPC/C/PS/TO in 4.5/4.5/1/1 molar ratio; PC/C/DPPG/TC in 5/4/1/1 molar ratio; PC/C/PG/TC in 5/4/1/1 molar ratio; PE/C/CL/TO in 4.5/4.5/1/1 molar ratio; and PC/C/DMPA/TO in 4.5/4.5/1/1 molar ratio can all be used. To incorporate other water-soluble materials, such as glucose, sucrose, methotrexate, Ponceau S, simply substitute the desired materials for IL-2 in Example 2. Also, other biologically active substances, such as set forth in Table 1, in suitable doses can be similarly substituted for IL-2 as in Example 2.

25
30

Example 6

In this example, the triolein in lipid components of above examples are substituted either singly or in combination by other triglycerides, vegetable oils, animal

-14-

2079666
fats, tocopherols, tocopherol esters, cholesteryl esters, or hydrocarbons with good results.

Example 7

To make liposomes smaller than that in the foregoing examples, and with reference to Examples 1 or 2, the mechanical strength or duration of shaking or homogenization in Step 4 of Example 1 or 2 was increased. To make liposomes larger, the mechanical strength or duration of shaking or homogenization in Step 4 of Example 1 or 2 was decreased.

The heterovesicular liposomes can be administered to the patients in the normal manner when it is desirable to provide two separate biologically active compounds to the patient for the particular purpose of treatment desired.

The dosage range appropriate for human use includes the range of 1-6000 mg/m to body surface area. The reason that this range is so large is that for some applications, such as subcutaneous administration, the dose required may be quite small, but for other applications, such as intraperitoneal administration, the dose desired to be used may be absolutely enormous. While doses outside the foregoing dose range may be given, this range encompasses the breadth of use for practically all the biologically active substances.

The multivesicular liposomes may be administered by any desired route; for example, intrathecal, intraperitoneal, subcutaneous, intravenous, intralymphatic, oral and submucosal, under many different kinds of epithelia including the bronchial epithelia, the gastrointestinal epithelia, the urogenital epithelia, and various mucous membranes of the body, and intramuscular.

When encapsulating more than two substances separately in chambers of a liposome, a third (or fourth) aqueous component containing the third or fourth biologically active substance is formed, mixed to form a third or fourth water in oil emulsion, and then combined

2078666

-15-

with the first and second emulsions and mixed to form a "chimeric" emulsion containing the three or more biologically active substances. The remainder of the process is the same as described when encapsulating two
5 biologically active compounds or substances.

The present invention, therefore, obtains the objects and ends and has the advantages mentioned as well as others inherent therein.

While examples of the invention have been given
10 for the purpose of disclosure, changes can be made therein which are within the spirit of the invention as defined by the appended claims.

What is claimed is:

-16-

Claims

1. A heterovesicular lipid vesicle or liposome having at least two different biologically active substances encapsulated in separate chambers of the same liposome.

2. A process for producing a heterovesicular lipid vesicle or liposome having at least two different biologically active substances separately encapsulated in aqueous chambers thereof comprising the steps of:

(a) providing a first lipid component dissolved in one or more organic solvents and adding into the said lipid component an immiscible first aqueous component containing a first biologically active substance to be encapsulated;

(b) forming a first water-in-oil emulsion from the first two immiscible components;

(c) providing a second lipid component dissolved in one or more organic solvents and adding into the said lipid component an immiscible second aqueous component containing a second substance to be encapsulated;

(d) forming a second water-in-oil emulsion from the second two immiscible components;

(e) forming a chimeric emulsion by combining the first water-in-oil emulsion and the second water-in-oil emulsion;

(f) transferring and immersing the product of step (e) in a third media that is immiscible with said organic solvents;

(g) dispersing the chimeric emulsion to form solvent spherules containing multiple droplets of the first aqueous component containing the first substance and the second aqueous component containing the second substance; and

-17-

(h) evaporating the organic solvents from the solvent spherules to form the heterovesicular liposomes.

3. The process according to Claim 2 wherein the first and second lipid components are a phospholipid or an admixture of several phospholipids.

4. The process according to Claim 2 wherein three or more water-in-oil emulsions containing three or more immiscible aqueous components are combined to form the chimeric emulsion.

5. The process according to Claim 2 wherein the first and second lipid components are identical.

6. The process according to Claim 3 wherein the phospholipids are selected from the group consisting of phosphatidylcholine, cardiolipin, phosphatidylethanolamine, sphingomyelin, lysophosphatidylcholine, phosphatidylserine, phosphatidylinositol, phosphatidylglycerol, and phosphatidic acid.

7. The process according to Claim 3 wherein the one or more of the lipid components contain a lipid with a net negative charge or charges.

8. The process according to Claim 3 wherein at least one of the phospholipids is provided in admixture with cholesterol.

9. The process according to Claim 3 wherein at least one of the phospholipids is provided in admixture with stearylamine.

-18-

10. The process according to Claim 2 wherein at least one of the first and second substances is a lipophilic biologically active material.

11. The process according to Claim 2 wherein at least one of the first and second lipid components is a neutral lipid either singly or in combination with a substance selected from the group consisting of triglycerides, vegetable oils, animal fats, tocopherols, tocopherol esters, cholesteryl esters, and hydrocarbons.

12. The process according to Claim 2 wherein the organic solvent is selected from the group consisting of ethers, hydrocarbons, halogenated hydrocarbons, halogenated ethers, esters, and combinations thereof.

13. The process according to Claim 2 wherein the hydrochloride is selected from the group consisting of hydrochloric acid, lysine hydrochloride, histidine hydrochloride and combinations thereof.

14. The process according to Claim 2 wherein the biologically active substance is hydrophilic.

15. The process according to Claim 14 wherein the hydrophilic biologically active substance is selected from the group consisting of interleukin-2, cytosine arabinoside, methotrexate, 5-fluorouracil, cisplatin, floxuridine, melphalan, mercaptopurine, thioguanine, thiotepa, vincristine, vinblastine, streptozocin, leuprolide, interferon, calcitonin, doxorubicin, daunorubicin, mitoxanthrone, amacrine, actinomycin, and bleomycin.

16. The process according to Claim 2 wherein the emulsification of the two components is carried out using

-19-

methods selected from the group consisting of mechanical agitation, ultrasonic energy, and nozzle atomization.

17. The process according to Claim 2 wherein the third aqueous component contains at least one acid-neutralizing agent.

18. The process according to Claim 17 wherein the acid-neutralizing agent is selected either singly or in combination from the group consisting of free-base lysine and free-base histidine.

19. The process according to Claim 17 wherein the third aqueous component is an aqueous solution further containing solutes selected from the group consisting of carbohydrates and aminoacids.

20. The process according to Claim 17 wherein the third aqueous component is an aqueous solution containing solutes selected either singly or in combination from the group consisting of glucose, sucrose, lactose, free-base lysine, and free-base histidine.

21. The process according to Claim 2 wherein the dispersion to form solvent spherules is carried out using methods selected from the group consisting of mechanical agitation, ultrasonic energy, and nozzle atomization.

22. The process according to Claim 2 wherein the evaporation of the organic solvent is provided by passing nitrogen gas over the second aqueous component.

-20-

23. The process of claim 2 where the biologically active substances to be encapsulated are selected from the group consisting of the compositions consisting of antiasthma compositions, antiarrhythmic compositions, tranquilizers, cardiac glycosides, hormones, steroids, antihypertensives, antidiabetics, antihistamines, antiparasitics, anticancer compounds, sedatives and analgesics, antibiotics, immunotherapies, vaccines, antifungal compounds, antihypotension compounds, antiviral compounds, proteins and glycoproteins, nucleic acids and analogs, and cell surface receptor blockers.

24. Heterovesicular liposomes made according to the method of claim 2.

25. A heterovesicular liposome containing at least two different biologically active substances encapsulated in separate chambers of the same liposome, at least one of the substances encapsulated in the presence of a hydrochloride.

26. The heterovesicular liposomes of claim 25, wherein the hydrochloride is selected from the group consisting of hydrochloric acid, lysine hydrochloride, histidine hydrochloride and combinations thereof.

27. A heterovesicular liposome containing at least two different biologically active substances encapsulated in separate chambers of the liposome, at least one of the substances encapsulated in the presence of hydrochloric acid or other acid hydrochlorides and a neutralizing agent.

28. The heterovesicular liposome of claim 25, wherein the biologically active compositions are selected from the group consisting of the compositions of antiasthma compositions, antiarrhythmic compositions, tranquilizers, cardiac glycosides, hormones, steroids, antihypertensives, antidiabetics, antihistamines, antiparasitics, anticancer compounds, sedatives and analgesics, antibiotics, immunotherapies, vaccines, antifungal compounds, antihypotension compounds, antiviral compounds, proteins and glycoproteins, nucleic acids and analogs, and cell surface receptor blockers.

-21-

29. The heterovesicular liposome of claim 27, wherein the biologically active compositions are selected from the group consisting of the compositions of antiasthma compositions, antiarrhythmic compositions, tranquilizers, cardiac glycosides, hormones, steroids, antihypertensives, antidiabetics, antihistamines, antiparasitics, anticancer compounds, sedatives and analgesics, antibiotics, immunotherapies, vaccines, antifungal compounds, antihypotension compounds, antiviral compounds, proteins and glycoproteins, nucleic acids and analogs, and cell surface receptor blockers.

30. A use of a heterovesicular liposome having two different biologically active substances encapsulated in separate chambers for the treatment of a patient.

31. A use of a heterovesicular liposome according to claim 24, 25, 26, 27, 28 or 29 for the treatment of a patient.

32. A heterovesicular lipid vesicle or liposome having at least two different biologically active substances encapsulated in separate chambers of the same liposome wherein,

the biologically active substances are selected from the group consisting of antiarrhythmic, antiasthma, antibiotic, anticancer, antidiabetic, antifungal, antihistamines, antihypertensives, antihypotension, antiparasitic, antiviral, cell surface, receptor blockers, glucose, cardiac glycosides, hormones, immunotherapies, nucleic acids and analogs, proteins and glycoproteins, sedatives and analgesic, steroids, tranquilizers, vaccines, and water.

33. The process of claim 2, wherein,

the biologically active substances are selected from the group consisting of antiarrhythmic, antiasthma, antibiotic, anticancer, antidiabetic, antifungal, antihistamines, antihypertensives, antihypotension, antiparasitic, antiviral, cell surface receptor blockers, glucose, cardiac glycosides, hormones, immunotherapies, nucleic acids and analogs, proteins and glycoproteins, sedatives and analgesic, steroids, tranquilizers, vaccines, and water.

-22-

34. The process of claim 23, wherein the substances are selected from the group consisting of antiasthma compositions selected from the group consisting of metaproterenol, aminophylline, theophylline, terbutaline, Tegretol, ephedrine, isoproterenol, adrenalin, norepinephrine; antiarrhythmic compositions selected from the group consisting of propanolol, atenolol, verapamil, captopril, isosorbide; tranquilizers selected from the group consisting of chlorpromazine, benzodiazepine, butyrophenones, hydroxyzines, meprobamate, phenothiazines, reserpine, thioxanthines; cardiac glycosides selected from the group consisting of digitalis, digitoxin, lanatoside C, digoxin; hormones selected from the group consisting of antidiuretic, corticosteroids, testosterone, estrogen, thyroid, growth, ACTH, progesterone, gonadotropin, mineralocorticoid, LH, LHRH FSH, calcitonin; steroids selected from the group consisting of prednisone, triamcinolone, hydrocortisone, dexamethasone, betamethasone, prednisolone; antihypertensives selected from the group consisting of apresoline, atenolol; antidiabetics selected from the group consisting of Diabinese, insulin; antihistamines selected from the group consisting of pyribenzamine, chlorpheniramine, diphenhydramine; antiparasitics selected from the group consisting of praziquantel, metronidazole, pentamidine; anticancer compounds selected from the group consisting of azathioprine, bleomycin, cyclophosphamide, adriamycin, daunorubicin, vincristine, methotrexate, 6-TG, 6-MP, vinblastine, VP-16, VM-26, cisplatin, FU; sedatives and analgesics selected from the group consisting of morphine, dilaudid, codeine, codeine-like synthetics, demerol, oxymorphone, phenobarbital, barbiturates; antibiotics selected from the group consisting of penicillin, tetracycline, erythromycin, cephalothin, imipenem, cefotaxime, carbenicillin, vancomycin, gentamicin, tobramycin, piperacillin, moxalactam, amoxicillin, ampicillin, cefazolin, cefadroxil, cefoxitin, other aminoglycosides; immunotherapies selected from the group consisting of interferon, interleukin-2, monoclonal antibodies, gammaglobulin; vaccines selected from the group consisting of influenza, respiratory syncytial, virus, Hemophilus influenza vaccine; antifungal compounds selected from the group consisting of amphotericin B, myconazole, muramyl dipeptide, clotrimazole; antihypotension compounds selected from the group consisting of dopamine, dextroamphetamine; antiviral compounds selected from the group consisting of acyclovir and derivatives, Winthrop-51711, ribavirin, rimantadine/amantadine, azidothymidine and derivatives, adenine arabinoside, amidine-type

-23-

protease inhibitors; proteins and glycoproteins selected from the group consisting of lymphokines, interleukins -1, 2, 3, 4, 5 and 6, cytokines, GM-CSF, M-CSF, G-CSF, tumor necrosis factor, inhibin, tumor growth factor, Mullerian inhibitors substance, nerve growth factor, fibroblast growth factor, platelet derived growth factor, coagulation factors (e.g. VIII, IX, VII), insulin, tissue plasminogen activator, histocompatibility antigen, oncogene products, myelin basic protein, collagen, fibronectin, laminin, other proteins made by recombinant DNA technology; nucleic acids and analogs selected from the group consisting of DNA, RNA, methylphosphonates and analogs; and cell surface receptor blockers.

35. The heterovesicular liposome of claim 28 or 29 where the biologically active compositions are selected from the group consisting of antiasthma compositions selected from the group consisting of metaproterenol, aminophylline, theophylline, terbutaline, Tegotol, ephedrine, isoproterenol, adrenalin, norepinephrine; antiarrhythmic compositions selected from the group consisting of propranolol, atenolol, verapamil, captopril, isosorbide; tranquilizers selected from the group consisting of chlorpromazine, benzodiazepine, butyrophenones, hydroxyzines, meprobamate, phenothiazines, reserpine, thioxanthines; cardiac glycosides selected from the group consisting of digitalis, digitoxin, lanatoside C, digoxin; hormones selected from the group consisting of antidiuretic, corticosteroids, testosterone, estrogen, thyroid, growth, ACTH, progesterone, gonadotropin, mineralocorticoid, LH, LHRH FSH, calcitonin; steroids selected from the group consisting of prednisone, triamcinolone, hydrocortisone, dexamethasone, betamethasone, prednisolone; antihypertensives selected from the group consisting of apresoline, atenolol; antidiabetics selected from the group consisting of Diabenese, insulin; antihistamines selected from the group consisting of pyribenzamine, chlorpheniramine, diphenhydramine; antiparasitics selected from the group consisting of praziquantel, metronidazole, pentamidine; anticancer compounds selected from the group consisting of azathioprine, bleomycin, cyclophosphamide, adriamycin, daunorubicin, vincristine, methotrexate, 6-TG, 6-MP, vinblastine, VP-16, VM-26, cisplatin, FU; sedatives and analgesics selected from the group consisting of morphine, dilaudid, codeine, codeine-like synthetics, demerol, oxymorphone, phenobarbital, barbiturates; antibiotics selected from

-24-

the group consisting of penicillin, tetracycline, erythromycin, cephalothin, imipenem, cefofaxime, carbenicillin, vancomycin, gentamycin, tobramycin, piperacillin, moxalactam, amoxicillin, ampicillin, cefazolin, cefadroxil, cefoxitin, other aminoglycosides; immunotherapies selected from the group consisting of interferon, interleukin-2, monoclonal antibodies, gammaglobulin; vaccines selected from the group consisting of influenza, respiratory syncytial, virus, Hemophilus influenza vaccine; antifungal compounds selected from the group consisting of amphotericin B, myconazole, muramyl dipeptide, clotrimazole; antihypotension compounds selected from the group consisting of dopamine, dextroamphetamine; antiviral compounds selected from the group consisting of acyclovir and derivatives, Winthrop-51711, ribavirin, rimantadine/amantadine, azidothymidine and derivatives, adenine arabinoside, amidine-type protease inhibitors; proteins and glycoproteins selected from the group consisting of lymphokines, interleukins -1, 2, 3, 4, 5 and 6, cytokines, GM-CSF, M-CSF, G-CSF, tumor necrosis factor, inhibin, tumor growth factor, Mullerian inhibitors substance, nerve growth factor, fibroblast growth factor, platelet derived growth factor, coagulation factors (e.g. VIII, IX, VII), insulin, tissue plasminogen activator, histocompatibility antigen, oncogene products, myelin basic protein, collagen, fibronectin, laminin, other proteins made by recombinant DNA technology; nucleic acids and analogs selected from the group consisting of DNA, RNA, methylphosphonates and analogs; and cell surface receptor blockers.

2078666

FIG. 7




FIG. 8




FIG. 5




FIG. 6




FIG. 2




FIG. 4




FIG. 1





FIG. 3



CONSTITUTE SHEET